Accelerate to discover

Back to filter

Related topics

Cytek webinar - the new age of spectral flow cytometry

Cytek Biosciences

Sep 9, 2019

The Cytek Aurora flow cytometer has made more than twenty-four color flow cytometry panels possible with only three...

New study resolves helicase dynamics and interactions during DNA replication using C-Trap

LUMICKS

Aug 30, 2019

Researchers from Rockefeller University used a C-Trap optical tweezers – fluorescence microscopy system to observe the...

Low-dose maging in a new preclinical total-body PET/CT scanner

Bruker Biospin

Aug 28, 2019

Ionizing radiation constitutes a health risk to imaging scientists and study animals. Both PET and CT produce ionizing...

Novel methods to analyze platelet activation with the NovoCyte flow cytometer

Acea Biosciences

Aug 26, 2019

Platelets are of large importance in medicine both for their essential role in hemostasis and thrombosis, as well as...

Sep 16, 2019

Bruker Plans to Develop World’s Highest Field Preclinical MRI System for Oncology and Neuroscience

Bruker Biospin

Aug 23, 2019

Bruker, a leading manufacturer of magnetic resonance imaging equipment, is working on the development of a powerful new...

Assessment of pro-arrhythmic effects using xCELLigence Cardio system and Pluricyte Cardiomyocytes

Acea Biosciences

Aug 21, 2019

The combination of Pluricyte Cardiomyocytes and the xCELLigence RTCA Cardio ECR system enables  detailed ...

Bruker announces acquisition of preclinical and molecular imaging research software provider PMOD

Bruker Biospin

Aug 19, 2019

The PMOD software is widely used for the analysis of positron emission tomography (PET) studies in neurology,...

Sep 16, 2019

Structural variants identified by Oxford Nanopore PromethION sequencing of the human genome

Sage Science

Aug 16, 2019

The BluePippin was used for High Pass DNA size selection prior to library construction. ONT Promethion was used for...

Show all topics (10)

Preclinical cardiac safety assesment

Mar 22, 2016

Over the last two decades, a number of blockbuster drugs have been withdrawn or have incurred safety warnings by regulatory agencies due to adverse cardiac effects. In addition, lead compounds or drug candidates are frequently terminated at late stages of drug development due to cardiac safety concerns. Both of these factors can significantly impact the overall cost of drug discovery; consequently, pharmaceutical companies and regulatory agencies have implemented procedures to address these issues.

Most, if not all, in vitro assay systems for cardiac safety are designed to screen for surrogates of arrhythmia, such as hERG channel interaction, rather than arrhythmia itself. Assays designed to screen for compounds that may affect repolarization and induce arrhythmia in the context of the whole heart or heart tissue are not implemented until much later in drug development. These include sophisticated, technically demanding, lowthroughput, and costly procedures such as the Purkinje fiber assay, ventricular wedge assay, and the Langendorff whole heart assay, or telemetry experiments in live and anesthetized animals. The field of preclinical cardiac safety can certainly benefit from an assay system that allows for integrated assessment of compound action on ion channel and non-ion channel targets involved in cardiac excitation-contraction coupling.

The RTCA Cardio Instrument in conjunction with iCell Cardiomyocytes comprises an assay system providing integrated assessment of compound action on multiple targets involved in heart function. This assay system can sensitively and quantitatively detect the effect of compounds on the major ion channels involved in heart function, namely calcium, sodium, and potassium channels. Another major advantage of the assay system is the time resolution. The RTCA Cardio Instrument has a data acquisition rate of 12.5 ms per well of a 96-well plate and can be used simultaneously to monitor acute and chronic drug effects up to days and weeks. The utility of the time-dependent monitoring of compound action on cardiomyocytes can be demonstrated by testing compounds that acutely and directly block hERG channels (E4031, cisapride, etc.) and compounds that interfere with protein trafficking (pentamidine) in a sub-chronic manner. The RTCA Cardio Instrument is able to detect the effects of these compounds on the beating rate and duration of iCell Cardiomyocytes.

The xCELLigence System RTCA Cardio Instrument, in conjunction with iCell Cardiomyocytes, represents a physiologically relevant and predictive assay system for preclinical cardio-safety assessment of lead compounds. The features of this assay system, including time resolution, dynamic monitoring of mechanical beating activity of cardiomyocytes, and 96-well throughput, will surely provide additional mechanistic and toxicity information for compound action on the heart.

Application
Product news

Related technologies: Real-time, label free cell analysis

Brand profile

Acea Biosciences

ACEA manufactures xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

Cardio Instrument is a high-resolution system for label-free-dual-mode monitoring of cardiomyocyte and cardiotoxicity testing

show detail

The new CardioECR system combines impedance and Multi Electrode Array (MEA) technology with a pacing function

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey